Shaolin Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Shaolin Capital Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23,662	Closed	-$140K	–	704
2022 Q4	$140K	Sell	23,662 -3,838	-14%	-$35.1K	﹤0.01%	428
2022 Q3	$193K	Hold	27,500	–	–	0.01%	467
2022 Q2	$399K	Hold	27,500	–	–	0.01%	510
2022 Q1	$1.03M	Buy	27,500 +3,525	+15%	+$163K	0.03%	453
2021 Q4	$1.87M	Sell	23,975 -30,092	-56%	-$2.82M	0.05%	405
2021 Q3	$5.45M	Buy	54,067 +715	+1%	+$71.3K	0.17%	161
2021 Q2	$5.32M	Buy	53,352 +1,326	+3%	+$132K	0.16%	144
2021 Q1	$5.11M	Buy	+52,026	New	+$5.2M	0.22%	93

Other funds holding SABS

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Shaolin Capital Management's SABS Position: Q1 2023 in Review

Shaolin Capital Management sold out of SAB Biotherapeutics (SABS) in Q1 2023, closing a stake of 23,662 shares — an estimated $140K sold.

Shaolin Capital Management first reported a position in SABS in Q1 2021 and held it in 8 quarters. The position peaked at $5.45M in Q3 2021. 39 funds tracked by Wall St. Rank hold SABS as of Q1 2023.

Shaolin Capital Management reported no remaining SAB Biotherapeutics position as of Q1 2023 after selling out during the quarter.
Shaolin Capital Management sold 23,662 SAB Biotherapeutics shares in Q1 2023, an estimated $140K.
Shaolin Capital Management first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 8 quarters.
Shaolin Capital Management's SAB Biotherapeutics position peaked at $5.45M in Q3 2021.
39 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2023.

Based on Shaolin Capital Management's 13F filing for Q1 2023, filed 15 May 2023.